Baidu
map

新疆药招:采集全国采购均价 试点城市自行采购

2017-09-17 佚名 新浪医药新闻

9月15日,新疆维吾尔自治区卫计委正式发布《2017年新疆维吾尔自治区公立医院药品集中采购工作操作方案》(以下简称《方案》),该《方案》最大特点如本文标题:网上采购价格采集7号文以后全国省级集中采购均价,同时允许试点城市在自治区采购平台上自行采购。新疆药招,并没有一味降价到底,但是方案之中,仍然杀器频祭,由于此次下发的只是《方案》,笔者将重点关注部分解读如下,其余评见方案介绍。

9月15日,新疆维吾尔自治区卫计委正式发布《2017年新疆维吾尔自治区公立医院药品集中采购工作操作方案》(以下简称《方案》),该《方案》最大特点如本文标题:网上采购价格采集7号文以后全国省级集中采购均价,同时允许试点城市在自治区采购平台上自行采购。新疆药招,并没有一味降价到底,但是方案之中,仍然杀器频祭,由于此次下发的只是《方案》,笔者将重点关注部分解读如下,其余评见方案介绍。

1 “省级集中采购均价”的定义模糊

《方案》中“网上集中采购药品实行动态管理”方面,指出,网上药品采购价格,在采购周期定期进行动态调整,对采购价格高于《国务院办公厅关于完善公立医院药品集中采购工作的指导意见》(简称7号文)文件执行后各省级集中采购均价的,将其调整为均价。这一点十分关键,首先明确了四个方面:

1、7号文执行以后的价格。也就是说,7号文执行之前目前仍然行之有效的价格,将不予采集。相信政策制定者也是考虑到时间久远,多年之前的价格已经没有采集必要,这一点为新疆的务实点赞。

2、均价采集的前提是省级价格。

7号文以来,随着深圳、上海两地GPO的开展,以及以浙江区域为首的各试点城市(县)单独集采,价格日益破碎化成为现实。福建药招更是摆脱了传统招标模式,采用了联合限价阳光采购,目前对外公布的一律是医保最高销售限价(不指向具体品规、企业),因此,新疆的方案,仅从文字表述上来看,是以省级价格为准。

3、采购均价的空间。如果看完前两点,有的药企要笑了,但笔者认为,千万莫笑得过早。《方案》中特别强调:7号文文件执行后各省级集中采购均价!什么是省级集中采购均价?可以理解为省级中标价格均价,也可以理解为省级中标价格在线交易价格均价,而对于有的省份,存在不同价格的,是先该省进行平均后再计算,还是全部打包进行价格平均?

4、对省级中标价格的理解。对于公开招标价格来说,省级价格往往就是中标价,但对于直接挂网品种来说,各省普遍对中标价的定义不一样:广西、江西,将直接挂网价格定义为“公开报价结果”,即企业自主报价,并不是实际意义上的中标价;湖北,则将直挂药品价格定义为“挂网价格”,在此价格之下,医院可以再次议价;江西,则干脆对各片区开展的二次议价价格不予公开,但在采购系统中能够查到。因此,相对于公开招标品规来说,中标价格能够较为清晰的界定,但对直接挂网品规,中标价其实已经丧失了原本赋予的含义,因此政策制定者,写了一句省级采购均价,潜台词即是:省级采购(实际)价格的平均价。

2 招标采购目录制定的不清晰

招标采购目录中,各省对招标采购药品的定义通常是医疗机构按照不低于上年度药品实际使用量的80%制定采购计划和预算,并具体到品种、剂型和规格,每种药品采购的剂型原则上不超过3种,每种剂型对应的规格原则上不超过2种,新疆基本也是遵循这个路子。但令人不解的是,《方案》在招标采购目录制定环节,特别强调,如果不在上报范围内但确属临床必须也可以上报。笔者认为,如果真正存在临床必须但不符合招标采购范围的产品,完全可以放到直接挂网目录中去,由医疗机构或联合体直接进行议价或价格确认,这样一方面能够实现哪里上报的品规在哪里产生销售,也能够实现价格协商市场最大化,如果直接放在公开招标采购目录中,是否会存在不可预知的价格风险?!千万不要“泼水的同时把孩子也泼了”。

3 试点城市自行采购的老梗

根据《方案》,试点城市成交价格明显低于区级中标价格的,区级中标价格应按试点城市成交价格进行调整。但方案未明确「明显低于」的具体量化指标(从目前来看,5%—10%是合理区间)。
4 耐人寻味的分组

此次《方案》分组,相当令人值得回味。第一组把在欧盟、美国、日本等发达国家(地区)上市销售的药品以及进口、中外合资(独资)的药品、通过仿制药一致性评价的药品、获得中国质量奖的药品分在一组,关于首仿(创),则没有了定义。而很多省份普遍分组是将过保护期专利药品、通过仿制药质量和疗效一致性评价的药品和首次仿(创)制药品分在一组,这也就基本上意味着进口药品和国产仿制品(暂未通过一致性评价)的角力,在新疆几乎就是不可能。

而反观第二组,则是国产药品要血拼的节奏:中药一级、二级保护品种、国家自然科学/科技进步/技术发明二等奖(含二等奖)等国产品规则分为了一组。所以,一组简直是一个“价格避风港”,欢迎来到一组!

除上述提到的因素,《方案》中还特别强调了两票制的作用、通过质量一致性评价在评标过程中的优势以及报价中要注意的方面(原则上不得高于上一轮同企业中标价)、基层医疗机构可以配备使用不超过15%的非基药零差率销售等等。总体来说,新疆方案延续以往风格,总体较为柔和,对药企来说,如果操作得当,完全可以实现以时间换空间的战略措施。无论如何,新疆药招已经正式开始,考验药企智慧的时候,到了。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1641591, encodeId=591c1641591de, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Fri Aug 31 19:41:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632525, encodeId=84d9163252583, content=<a href='/topic/show?id=b8618e585bb' target=_blank style='color:#2F92EE;'>#药招#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87585, encryptionId=b8618e585bb, topicName=药招)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40c21929525, createdName=xirongguo, createdTime=Tue May 08 11:41:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941891, encodeId=7be219418911f, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Mar 25 11:41:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532713, encodeId=60a61532e13a3, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Tue Sep 19 04:41:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245376, encodeId=83d12453e635, content=考验药企智慧的时候.到了., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Sep 18 17:52:50 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245114, encodeId=3334245114de, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Sep 17 22:45:06 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245081, encodeId=3ed22450816d, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Sep 17 20:42:24 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245073, encodeId=4c612450e3ac, content=期盼好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba591726358, createdName=欣怡b88dc255, createdTime=Sun Sep 17 19:52:26 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245035, encodeId=1bb4245035fc, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Sun Sep 17 14:21:53 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1641591, encodeId=591c1641591de, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Fri Aug 31 19:41:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632525, encodeId=84d9163252583, content=<a href='/topic/show?id=b8618e585bb' target=_blank style='color:#2F92EE;'>#药招#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87585, encryptionId=b8618e585bb, topicName=药招)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40c21929525, createdName=xirongguo, createdTime=Tue May 08 11:41:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941891, encodeId=7be219418911f, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Mar 25 11:41:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532713, encodeId=60a61532e13a3, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Tue Sep 19 04:41:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245376, encodeId=83d12453e635, content=考验药企智慧的时候.到了., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Sep 18 17:52:50 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245114, encodeId=3334245114de, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Sep 17 22:45:06 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245081, encodeId=3ed22450816d, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Sep 17 20:42:24 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245073, encodeId=4c612450e3ac, content=期盼好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba591726358, createdName=欣怡b88dc255, createdTime=Sun Sep 17 19:52:26 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245035, encodeId=1bb4245035fc, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Sun Sep 17 14:21:53 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2018-05-08 xirongguo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1641591, encodeId=591c1641591de, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Fri Aug 31 19:41:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632525, encodeId=84d9163252583, content=<a href='/topic/show?id=b8618e585bb' target=_blank style='color:#2F92EE;'>#药招#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87585, encryptionId=b8618e585bb, topicName=药招)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40c21929525, createdName=xirongguo, createdTime=Tue May 08 11:41:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941891, encodeId=7be219418911f, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Mar 25 11:41:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532713, encodeId=60a61532e13a3, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Tue Sep 19 04:41:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245376, encodeId=83d12453e635, content=考验药企智慧的时候.到了., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Sep 18 17:52:50 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245114, encodeId=3334245114de, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Sep 17 22:45:06 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245081, encodeId=3ed22450816d, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Sep 17 20:42:24 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245073, encodeId=4c612450e3ac, content=期盼好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba591726358, createdName=欣怡b88dc255, createdTime=Sun Sep 17 19:52:26 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245035, encodeId=1bb4245035fc, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Sun Sep 17 14:21:53 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1641591, encodeId=591c1641591de, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Fri Aug 31 19:41:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632525, encodeId=84d9163252583, content=<a href='/topic/show?id=b8618e585bb' target=_blank style='color:#2F92EE;'>#药招#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87585, encryptionId=b8618e585bb, topicName=药招)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40c21929525, createdName=xirongguo, createdTime=Tue May 08 11:41:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941891, encodeId=7be219418911f, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Mar 25 11:41:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532713, encodeId=60a61532e13a3, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Tue Sep 19 04:41:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245376, encodeId=83d12453e635, content=考验药企智慧的时候.到了., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Sep 18 17:52:50 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245114, encodeId=3334245114de, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Sep 17 22:45:06 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245081, encodeId=3ed22450816d, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Sep 17 20:42:24 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245073, encodeId=4c612450e3ac, content=期盼好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba591726358, createdName=欣怡b88dc255, createdTime=Sun Sep 17 19:52:26 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245035, encodeId=1bb4245035fc, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Sun Sep 17 14:21:53 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-19 wolongzxh
  5. [GetPortalCommentsPageByObjectIdResponse(id=1641591, encodeId=591c1641591de, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Fri Aug 31 19:41:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632525, encodeId=84d9163252583, content=<a href='/topic/show?id=b8618e585bb' target=_blank style='color:#2F92EE;'>#药招#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87585, encryptionId=b8618e585bb, topicName=药招)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40c21929525, createdName=xirongguo, createdTime=Tue May 08 11:41:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941891, encodeId=7be219418911f, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Mar 25 11:41:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532713, encodeId=60a61532e13a3, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Tue Sep 19 04:41:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245376, encodeId=83d12453e635, content=考验药企智慧的时候.到了., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Sep 18 17:52:50 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245114, encodeId=3334245114de, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Sep 17 22:45:06 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245081, encodeId=3ed22450816d, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Sep 17 20:42:24 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245073, encodeId=4c612450e3ac, content=期盼好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba591726358, createdName=欣怡b88dc255, createdTime=Sun Sep 17 19:52:26 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245035, encodeId=1bb4245035fc, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Sun Sep 17 14:21:53 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-18 fengyqf

    考验药企智慧的时候.到了.

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1641591, encodeId=591c1641591de, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Fri Aug 31 19:41:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632525, encodeId=84d9163252583, content=<a href='/topic/show?id=b8618e585bb' target=_blank style='color:#2F92EE;'>#药招#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87585, encryptionId=b8618e585bb, topicName=药招)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40c21929525, createdName=xirongguo, createdTime=Tue May 08 11:41:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941891, encodeId=7be219418911f, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Mar 25 11:41:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532713, encodeId=60a61532e13a3, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Tue Sep 19 04:41:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245376, encodeId=83d12453e635, content=考验药企智慧的时候.到了., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Sep 18 17:52:50 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245114, encodeId=3334245114de, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Sep 17 22:45:06 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245081, encodeId=3ed22450816d, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Sep 17 20:42:24 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245073, encodeId=4c612450e3ac, content=期盼好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba591726358, createdName=欣怡b88dc255, createdTime=Sun Sep 17 19:52:26 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245035, encodeId=1bb4245035fc, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Sun Sep 17 14:21:53 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-17 130****4638

    学习了谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1641591, encodeId=591c1641591de, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Fri Aug 31 19:41:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632525, encodeId=84d9163252583, content=<a href='/topic/show?id=b8618e585bb' target=_blank style='color:#2F92EE;'>#药招#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87585, encryptionId=b8618e585bb, topicName=药招)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40c21929525, createdName=xirongguo, createdTime=Tue May 08 11:41:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941891, encodeId=7be219418911f, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Mar 25 11:41:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532713, encodeId=60a61532e13a3, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Tue Sep 19 04:41:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245376, encodeId=83d12453e635, content=考验药企智慧的时候.到了., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Sep 18 17:52:50 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245114, encodeId=3334245114de, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Sep 17 22:45:06 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245081, encodeId=3ed22450816d, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Sep 17 20:42:24 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245073, encodeId=4c612450e3ac, content=期盼好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba591726358, createdName=欣怡b88dc255, createdTime=Sun Sep 17 19:52:26 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245035, encodeId=1bb4245035fc, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Sun Sep 17 14:21:53 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-17 天涯183

    非常好的文章.学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1641591, encodeId=591c1641591de, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Fri Aug 31 19:41:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632525, encodeId=84d9163252583, content=<a href='/topic/show?id=b8618e585bb' target=_blank style='color:#2F92EE;'>#药招#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87585, encryptionId=b8618e585bb, topicName=药招)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40c21929525, createdName=xirongguo, createdTime=Tue May 08 11:41:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941891, encodeId=7be219418911f, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Mar 25 11:41:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532713, encodeId=60a61532e13a3, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Tue Sep 19 04:41:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245376, encodeId=83d12453e635, content=考验药企智慧的时候.到了., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Sep 18 17:52:50 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245114, encodeId=3334245114de, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Sep 17 22:45:06 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245081, encodeId=3ed22450816d, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Sep 17 20:42:24 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245073, encodeId=4c612450e3ac, content=期盼好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba591726358, createdName=欣怡b88dc255, createdTime=Sun Sep 17 19:52:26 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245035, encodeId=1bb4245035fc, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Sun Sep 17 14:21:53 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-17 欣怡b88dc255

    期盼好消息

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1641591, encodeId=591c1641591de, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Fri Aug 31 19:41:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632525, encodeId=84d9163252583, content=<a href='/topic/show?id=b8618e585bb' target=_blank style='color:#2F92EE;'>#药招#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87585, encryptionId=b8618e585bb, topicName=药招)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40c21929525, createdName=xirongguo, createdTime=Tue May 08 11:41:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941891, encodeId=7be219418911f, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Mar 25 11:41:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532713, encodeId=60a61532e13a3, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Tue Sep 19 04:41:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245376, encodeId=83d12453e635, content=考验药企智慧的时候.到了., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Sep 18 17:52:50 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245114, encodeId=3334245114de, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Sep 17 22:45:06 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245081, encodeId=3ed22450816d, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Sep 17 20:42:24 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245073, encodeId=4c612450e3ac, content=期盼好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba591726358, createdName=欣怡b88dc255, createdTime=Sun Sep 17 19:52:26 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245035, encodeId=1bb4245035fc, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Sun Sep 17 14:21:53 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-17 中医痴

    不错的.学习了.谢谢分享!

    0

相关资讯

又一城市GPO搅局 广东药招或将变天?!

8月15日,广东省揭阳市人民政府办公室正式印发了《揭阳市城市公立医院综合改革实施方案》,提出将执行国家和省有关公立医院药品集中采购的政策,可以市为单位在省级药品集中采购平台上自行采购药品,成交价格不得高于省级中标价格。这是继佛山、清远之后,第三个正式下发医改方案,提出以市为单位自行采购的地区。

Baidu
map
Baidu
map
Baidu
map